NewsLatest News

bt_bb_section_bottom_section_coverage_image
Alliance Promotion Microbiote devient une Association et poursuit la structuration de la filière française du microbiote

Lyon- France – le 20 janvier 2022 – Créée en mars 2021, APM, qui compte 22 membres, est le fruit de l’union d’acteurs publics et privés engagés dans la promotion de la science émergente du microbiote. Porte-parole et fédérateur des acteurs majeurs du développement, de la production et de la commercialisation d’innovations thérapeutiquesliées au microbiote...

Improving respiratory health through live biotherapeutic products

Of all the respiratory diseases, one of them – COVID-19 – has been the focus of most of the research and attention over the past two years. While surely justified, this has had the effect of diverting resources away from the study of chronic respiratory diseases that urgently require solutions for clinical unmet needs: chronic...

Highlights of the 9th Microbiome R&D and Business Collaboration Forum – Europe

Many colleagues in the microbiome industry were able to gather in person once again for Global Engage’s 9thMicrobiome R&D and Business Collaboration Forum: Europe. The event had a wide-ranging program covering microbiome industry updates, and was held in Rotterdam, the Netherlands, October 26-27, 2021. The presentations were a combination of live and virtual. From the...

EverImmune engages Biose Industrie to manufacture its leading oncology-related live biotherapeutic

Microbiome oncology company turns to world-leading CDMO to handle the challenges of manufacturing and scale-up Microbiome-focused oncology drug company everImmune, a spin-out from France’s top cancer research center, has signed an agreement with contract development and manufacturing organization (CDMO) Biose Industrie to manufacture the drug substance and finished drug product for its leading live biotherapeutic...

What makes a winning microbiome company? Panel Discussion offers tips for company success in funding and development

At Pharmabiotics 2021 Conference & Partnering, Adrien Nivoliez, Biose Industrie CEO, held an Interactive Roundtable Discussion called Microbiome Therapeutics – the investment cycle from discovery to commercialization. Nivoliez spoke with Denise Kelly, Investment Advisor at Seventure Partners, and Paul Wagner, President & CEO of Forte Biosciences, about how microbiome companies can succeed in getting the...

The latest approaches in microbiome drug development: summary of the 5th MICROBIOME MOVEMENT DRUG DEVELOPMENT (MMDD) summit Europe

Hundreds of companies around the world are currently working on how to leverage human microbiome research for new clinical solutions – with at least €900M invested in microbiome-focused companies in 2020. The Microbiome Movement Drug Development Summit Europe, held 27-29thJanuary as a digital event, provided an opportunity to hear from some of the leading companies and learn...